Disease · MONDO_0004781

acute myocardial infarction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute myocardial infarction. Diseases, record MONDO_0004781. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004781

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute myocardial infarction; Open Targets
Open Targets ID: MONDO_0004781; Open Targets
Other names: AMI, acute myocardial infarction (disease), myocardial infarction (disease), acute; Open Targets
Disease Ontology: DOID:9408; Disease Ontology
NCI Thesaurus: C35204; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 82 drugs, from DailyMed and TTD; Open Targets

Drugs82

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TENECTEPLASE	CHEMBL2108791	Enzyme	Approval	DailyMed	8	6	6	Drugs and targets
RIDOGREL	CHEMBL280728	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TISOKINASE	CHEMBL2108105	Enzyme	Approval	TTD	1	0	0	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
ABCIXIMAB	CHEMBL1201584	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Phase 3	ClinicalTrials.gov	4	4	2	Drugs and targets
DEXTROSE	CHEMBL1222250	Small molecule	Phase 3	ClinicalTrials.gov	4	4	1	Drugs and targets
PRASUGREL	CHEMBL1201772	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 82

See all 82 drugs

Targets96

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor	6	Adrenergic receptor agonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
P2RY12	P2Y purinoceptor 12	5	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor; Purinergic receptor P2Y12 negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/64805	Drugs and targets
ADRB2	Adrenergic receptor	4	Adrenergic receptor agonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 3	https://conductscience.org/library/genes/1441	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Phase 2	https://conductscience.org/library/genes/2057	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3	HMG-CoA reductase inhibitor	Phase 2	https://conductscience.org/library/genes/3156	Drugs and targets
PLAT	Tissue-type plasminogen activator	3	Tissue-type plasminogen activator exogenous protein	Approval	https://conductscience.org/library/genes/5327	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	2	Type-1 angiotensin II receptor antagonist	Phase 3	https://conductscience.org/library/genes/185	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets

1 to 10 of 96

See all 96 targets

Trials83

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01088503	Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome		12,227	2016-01-29	Acute Coronary Syndrome	PRASUGREL	Its record names the disease	ClinicalTrials.gov
NCT00433966	Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction	Phase 3	3,602	2017-12-04	Myocardial Infarction	BIVALIRUDIN, HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT00046228	A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)	Phase 3	2,461	2009-05-15	Myocardial Infarction	ABCIXIMAB, RETEPLASE	Its record names the disease	ClinicalTrials.gov
NCT00623623	STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction	Phase 3	1,899	2019-08-01	Myocardial Infarction	CLOPIDOGREL, ENOXAPARIN, TENECTEPLASE	Its record names the disease	ClinicalTrials.gov
NCT00091507	IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.	Phase 3	911	2013-01-30	Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive	DEXTROSE, INSULIN HUMAN, POTASSIUM	Its record names the disease	ClinicalTrials.gov
NCT03151993	Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS	Phase 3	336	2025-04-02	Ischemic Stroke	ALTEPLASE	Its record names the disease	ClinicalTrials.gov
NCT03470441	A Study of Acute Myocardial Infarction Using FDY-5301	Phase 2	120	2021-12-14	Acute Myocardial Infarction, STEMI	SODIUM IODIDE	Its record names the disease	ClinicalTrials.gov
NCT04082442	Evolocumab in Patients With Acute MI	Phase 2	100	2025-10-23	Acute Coronary Syndrome	EVOLOCUMAB	Its record names the disease	ClinicalTrials.gov
NCT03487445	A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack	Phase 2	48	2021-08-25	Acute Myocardial Infarction	SELATOGREL	Its record names the disease	ClinicalTrials.gov
NCT02419937	Short-Term Application of Tocilizumab Following Myocardial Infarction	Not applicable	28	2017-11-17	Myocardial Infarction	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 83

See all 83 trials

Comparisons in its trials48

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding	89 of 1,800	149 of 1,802	3,602	NCT00433966	Trial comparisons
Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events	379 of 1,800	377 of 1,802	3,602	NCT00433966	Trial comparisons
Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events	98 of 1,800	99 of 1,802	3,602	NCT00433966	Trial comparisons
Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events	166 of 1,800	218 of 1,802	3,602	NCT00433966	Trial comparisons
Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Ischemic Target Lesion Revascularization	98 of 2,257	54 of 749	3,006	NCT00433966	Trial comparisons
Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis	181 of 2,257	59 of 749	3,006	NCT00433966	Trial comparisons
Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke	117 of 949	135 of 948	1,897	NCT00623623	Trial comparisons
Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Shock	59 of 949	73 of 948	1,897	NCT00623623	Trial comparisons
Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Ischaemic Stroke	6 of 949	3 of 948	1,897	NCT00623623	Trial comparisons
Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Congestive Heart Failure (CHF)	57 of 949	72 of 948	1,897	NCT00623623	Trial comparisons

1 to 10 of 48

See all 48 comparisons in its trials

Papers from its trials174

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40375762	RESULT	1	PubMed
32665641	RESULT	1	PubMed
31535829	RESULT	1	PubMed
31529295	RESULT	1	PubMed
31118574	RESULT	1	PubMed
30990260	RESULT	1	PubMed
28605608	RESULT	1	PubMed
26655874	RESULT	1	PubMed
26378978	RESULT	1	PubMed
26330422	RESULT	1	PubMed

1 to 10 of 174

See all 174 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004781

GET https://conductscience.org/api/diseases/v1/MONDO_0004781/drugs?page=2

API reference For AI assistants